EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Evaluation of danazol treatment of women with fibrocystic disease of breast



Evaluation of danazol treatment of women with fibrocystic disease of breast



Polski Tygodnik Lekarski 44(32-33): 771-773



The results of treatment of 20 female patients with fibrocystic degeneration of the breast with danazol are discussed. Diagnosis was made with the aid of mammography. Danazol was administered in the dose of 200 mg twice a day for 2 months, followed by 100 mg thrice a day, and 100 mg twice a day for further 2 months. An improvement in the clinical symptoms, decrease in LH, FSH, estradiol and progesterone levels was produced by danazol. The drug did not change LH response to LH-RH stimulation while blockade of dopaminergic receptors with metoclopramide decreased PRL response.

(PDF emailed within 1 workday: $29.90)

Accession: 040065069

Download citation: RISBibTeXText

PMID: 2701752



Related references

Aspects of fibrocystic disease of the breast. Treatment with danazol. Postgraduate Medical Journal 55 Suppl 5: 48-51, 1979

Reduction of cysts in fibrocystic breast disease during and after danazol treatment. Annals of the New York Academy of Sciences 464(none): 622-625, 1986

Treatment of fibrocystic breast disease with danazol. A multicenter study. Minerva Ginecologica 40(7): 427-433, 1988

Danol (danazol) in the treatment of fibrocystic breast disease with mastodynia. Casopis Lekaru Ceskych 128(7): 209-211, 1989

A french double blind crossover study danazol vs. placebo in the treatment of severe fibrocystic breast disease. European Journal of Gynaecological Oncology 5(2): 85-89, 1984

Danazol treatment of severely symptomatic fibrocystic breast disease and long-term follow-up--the Hjørring project. Acta Obstetricia et Gynecologica Scandinavica. Supplement 123: 159-176, 1984

A French double-blind crossover study (danazol versus placebo) in the treatment of severe fibrocystic breast disease. European Journal of Gynaecological Oncology 5(2): 85-89, 1984

Danazol for fibrocystic disease of the breast. Medical Letter on Drugs and Therapeutics 23(2): 5-6, 1981

Tamoxifen effects on treatment fibrocystic breast disease in women. Saudi Medical Journal 27(4): 565-566, 2006

Fibrocystic disease of the breast in premenopausal women histohormonal correlation and response to lhrh analog treatment. American Journal of Obstetrics & Gynecology 164(5 PART 1): 1181-1189, 1991

Critical, morphological, and histopathogenic considerations on fibrocystic breast disease; fibrocystic disease and carcinoma of the breast. Archivio Italiano di Anatomia E Istologia Patologica 24(6): 473-514, 1951

Anovulation and increased androgenic activity as breast cancer risk in women with fibrocystic disease of the breast. Cancer Research 38(9): 3051-3054, 1978

Prostate specific antigen molecular forms in breast cyst fluid and serum of women with fibrocystic breast disease. Journal of Clinical Laboratory Analysis 13(2): 75-81, 1999

Danazol for treatment of fibrocystic mastopathy. Zentralblatt für Gynakologie 117(9): 457-465, 1995